VEGFA and wet macular degeneration: Conbercept/Lumitin/KH902 (Chengdu Kanghong Biotech Company, Chengdu, China) is a new anti-VEGF antibody, approved by China State FDA for the treatment of wet AMD in 2013 after completion of the Phase II AURORA trial (NCT01157715) [105] and Phase III PHOENIX trial (NCT01436864) [106].